IRIS
AMATI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 974
NA - Nord America 958
EU - Europa 441
SA - Sud America 196
AF - Africa 24
OC - Oceania 8
Totale 2.601
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 919
SG - Singapore 529
CN - Cina 288
BR - Brasile 174
IT - Italia 107
FI - Finlandia 86
IE - Irlanda 62
GB - Regno Unito 47
DE - Germania 38
HK - Hong Kong 35
IN - India 35
SE - Svezia 31
VN - Vietnam 28
RU - Federazione Russa 25
CA - Canada 22
BD - Bangladesh 12
MX - Messico 11
TR - Turchia 10
AR - Argentina 9
JP - Giappone 8
ES - Italia 7
PL - Polonia 7
AU - Australia 6
NL - Olanda 6
FR - Francia 5
IQ - Iraq 5
KE - Kenya 5
ZA - Sudafrica 5
EC - Ecuador 4
LT - Lituania 4
MA - Marocco 4
NG - Nigeria 4
AE - Emirati Arabi Uniti 3
AO - Angola 3
PE - Perù 3
PH - Filippine 3
AL - Albania 2
BO - Bolivia 2
CR - Costa Rica 2
DZ - Algeria 2
GR - Grecia 2
JO - Giordania 2
LK - Sri Lanka 2
LV - Lettonia 2
NZ - Nuova Zelanda 2
PK - Pakistan 2
PT - Portogallo 2
UA - Ucraina 2
UZ - Uzbekistan 2
VE - Venezuela 2
AT - Austria 1
AZ - Azerbaigian 1
CO - Colombia 1
DM - Dominica 1
DO - Repubblica Dominicana 1
HN - Honduras 1
HU - Ungheria 1
ID - Indonesia 1
JM - Giamaica 1
KG - Kirghizistan 1
KR - Corea 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MY - Malesia 1
NO - Norvegia 1
NP - Nepal 1
QA - Qatar 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
TM - Turkmenistan 1
TN - Tunisia 1
UY - Uruguay 1
Totale 2.601
Salva come PNG Salva come JPEG
Città #
Singapore 180
Shanghai 154
Ashburn 136
The Dalles 130
Boardman 108
New York 88
Helsinki 86
Beijing 76
Dallas 68
Dublin 61
Los Angeles 43
Hong Kong 30
Milan 24
London 23
Naples 22
Moscow 19
Pune 17
São Paulo 17
Chandler 14
Santa Clara 13
Seattle 11
Chennai 9
Council Bluffs 9
Assago 8
Ho Chi Minh City 8
Shijiazhuang 8
Brooklyn 7
Chicago 7
Montreal 7
Warsaw 7
Ankara 6
Boston 6
Denver 6
Falkenstein 6
Rio de Janeiro 6
San Francisco 6
Casal di Principe 5
Mexico City 5
Phoenix 5
Stockholm 5
Wanchai 5
Atlanta 4
Benin City 4
Hangzhou 4
Johannesburg 4
Nairobi 4
Orem 4
Santo André 4
Southwark 4
Amsterdam 3
Cagliari 3
Da Nang 3
Dolianova 3
Florence 3
Goiânia 3
Guangzhou 3
Guildford 3
Hanoi 3
Montecassiano 3
Munich 3
Poplar 3
Presidente Prudente 3
St Petersburg 3
Sydney 3
São José do Rio Preto 3
Toronto 3
Amman 2
Asagayakita 2
Assendelft 2
Athens 2
Auckland 2
Baghdad 2
Belo Horizonte 2
Berlin 2
Birmingham 2
Bắc Ninh 2
Calgary 2
Campinas 2
Chapecó 2
Cotia 2
Curitiba 2
Daiba 2
Delhi 2
Dhaka 2
Etobicoke 2
Frankfurt am Main 2
Guarulhos 2
Johnson City 2
Kentville 2
Kirkuk 2
La Paz 2
Lawrence 2
Lima 2
Luanda 2
Maceió 2
Manchester 2
Melbourne 2
Miami 2
Montes Claros 2
Newark 2
Totale 1.602
Salva come PNG Salva come JPEG
Nome #
Diagnosis and management of patients with alpha 1-antitrypsin deficiency: an Italian perspective 95
COVID-19 in Immunocompromised Patients: A Systematic Review 86
Community-acquired pneumonia 74
Cardiovascular Complications in Community-Acquired Pneumonia 58
COVID-19 Network: the response of an Italian Reference Institute to research challenges about a new pandemia 58
COVID-19 in lung transplant recipients: A case series from Milan, Italy 57
An extensive bundle of tests is needed to detect treatable causes of bronchiectasis (Bx) 54
Treatable traits in interstitial lung diseases: a call to action 53
Cardiovascular side-effects of common antibiotics 53
Microbial Dysregulation of the Gut-Lung Axis in Bronchiectasis 52
Diagnosis and Initial Investigation of Bronchiectasis 51
COVID-19 multidisciplinary high dependency unit: the Milan model 50
Post-COVID-19 sequelae 50
Comparison of different sets of immunological tests to identify treatable immunodeficiencies in adult bronchiectasis patients 50
Comparison of different conditions for DNA extraction in sputum - a pilot study 49
Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia 49
Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases 49
Early Phases of COVID-19 Are Characterized by a Reduction in Lymphocyte Populations and the Presence of Atypical Monocytes 47
Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia 47
Hepatic and pulmonary involvement in a patient with PR3-ANCA vasculitis following SARS-CoV-2 vaccination: a case report 45
How to Identify Causes and Predisposing Factors in Bronchiectasis 45
Bacterial Patterns and Empiric Antibiotic Use in COPD Patients With Community-Acquired Pneumonia 44
Alpha1-Antitrypsin Inherited Variants in Patients With Bronchiectasis 44
Identify Drug-Resistant Pathogens in Patients with Community-Acquired Pneumonia 44
What is the best technique to extract bacterial DNA from sputum? 44
Antibiotics for lung disease and cancer 44
Genetic and Serum Screening for Alpha-1-Antitrypsin Deficiency in Adult Patients with Cystic Fibrosis: A Single-Center Experience 43
Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review 42
Dysregulation of the microbial ‘gut-lung’ axis in bronchiectasis 42
Prognostic parameters of in-hospital mortality in COVID-19 patients-An Italian experience 41
Investigating the Etiology of Bronchiectasis: You Do Not Find What You Do Not Look For 40
Respiratory failure in COVID-19: a patient's perspective and clinical cases 39
Site of care and multidisciplinary approach 38
Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series 38
Diagnostic delay in bronchiectasis: an Italian perspective 37
Neutrophil elastase in bronchiectasis 36
When and how ruling out cystic fibrosis in adult patients with bronchiectasis 36
Overweight and obesity in adults with cystic fibrosis: An Italian multicenter cohort study 35
The biology of pulmonary exacerbations in bronchiectasis 35
Emerging Resistance of Gram Negative Pathogens in Community-Acquired Pneumonia 35
Protease-Antiprotease Imbalance in Bronchiectasis 34
T2-High Endotype and Response to Biological Treatments in Patients with Bronchiectasis 33
Innate and Adaptive Lymphocytes in Non-Tuberculous Mycobacteria Lung Disease: A Review 32
Phenotyping in bronchiectasis: are we moving toward a personalized medicine? 32
Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis 32
Unmet needs and perspectives in rheumatoid arthritis-associated interstitial lung disease: A critical review 31
Walking the path of treatable traits in interstitial lung diseases 30
Immunodeficiencies and CFTR dysfunction: results from a systematic screening in a cohort of adults with cystic fibrosis and CFTR-related disorders 30
Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19-hospitalized patients 30
SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity 30
First Report of the Prevalence at Baseline and after 1-Year Follow-Up of Treatable Traits in Interstitial Lung Diseases 30
Respiratory viruses in stable bronchiectasis: A multicenter evaluation in Northern Italy 29
Risk factors and guideline adherence of empiric antibiotic use in community-acquired pneumonia 29
One Size Does Not Fit All: Moving Towards a Personalized Approach for Steroids in COVID-19 29
Pro-resolving and pro-inflammatory fatty acid-derived mediators in sputum of stable state bronchiectasis patients 28
Nontuberculous mycobacteria infection and pulmonary disease in bronchiectasis 28
Treatable Traits in Systemic Sclerosis 27
Response to: are there over 200 distinct types of interstitial lung diseases? 27
Switching to nebulised short acting bronchodilators does not increase the risk of arrhythmia in patients hospitalized with a COPD exacerbation 27
Predictors of Helmet CPAP Failure in COVID-19 Pneumonia: A Prospective, Multicenter, and Observational Cohort Study 27
Microbial Inflammatory Networks in Bronchiectasis Exacerbators With Pseudomonas aeruginosa 26
Lung Recruitability of COVID-19 Pneumonia in Patients Undergoing Helmet CPAP 24
Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis 23
Treatable traits and challenges in the clinical management of non-tuberculous mycobacteria lung disease in people with cystic fibrosis 23
Relationship Between Lung Volumes and Heterogeneity in the Response to Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease 22
Glucocorticoid Therapy in COVID-19 21
Vasoactive drugs for the treatment of pulmonary hypertension associated with interstitial lung diseases: a systematic review 17
Totale 2.680
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.224
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.224
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202211 0 0 0 0 0 0 0 0 2 3 4 2
2022/2023225 4 3 3 5 6 0 63 8 32 63 27 11
2023/2024715 53 64 122 67 32 107 68 31 9 45 50 67
2024/2025906 15 7 17 24 32 105 55 35 204 209 93 110
2025/2026823 322 130 74 114 130 53 0 0 0 0 0 0
Totale 2.680